Company intelligence / Profile preview

Systemed

Dalian, Liaoning, China

Ownership: Private
Development stage: Other

Overview

Dalian Systemed is a biotechnology company headquartered in Dalian, China, that specializes in the discovery and development of innovative small molecule therapeutics using a systems biology-driven approach. The company leverages its proprietary platform to identify novel drug targets and optimize lead compounds, primarily focusing on metabolic diseases and oncology. Its lead clinical candidate, SY-001, is a GPR119 agonist currently in Phase 2 development for the treatment of Type 2 Diabetes. By integrating computational biology with experimental validation, Systemed aims to accelerate the drug discovery process and address significant unmet medical needs in chronic and complex diseases.

Therapeutic areas: OncologyEndocrinology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Systemed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Systemed.

Explore the full profile